Clinical Trials Logo

Filter by:
NCT ID: NCT02799602 Completed - Clinical trials for Metastatic Hormone-sensitive Prostate Cancer

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

ARASENS
Start date: November 30, 2016
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.

NCT ID: NCT02799381 Completed - Clinical trials for Parkinson's Disease (PD)

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

DYSCOVER
Start date: February 9, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to examine the effect of levodopa-carbidopa intestinal gel (LCIG) compared with optimized medical treatment (OMT) on dyskinesia in participants with advanced Parkinson's disease (PD).

NCT ID: NCT02799290 Completed - Clinical trials for Wound Healing Disturbance of

Adipose Tissue Extract and Platelet-rich Plasma Use for Wound Healing

Start date: June 2015
Phase: Phase 2
Study type: Interventional

Adipose Tissue Extract (ATE) has been found to be an autologous source of growth factors with proven in vitro angiogenic and adipogenic properties.It is obtained by a simple lipoaspirate procedure. We sought to compare the effect of ATE with another known source, platelet-rich plasma to compare the wound healing characteristics on skin graft donor sites.

NCT ID: NCT02797951 Completed - Clinical trials for Chronic Cluster Headache

A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache

Start date: July 13, 2016
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).

NCT ID: NCT02795676 Completed - Fabry Disease Clinical Trials

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

BALANCE
Start date: June 2016
Phase: Phase 3
Study type: Interventional

This was a randomized, double-blind, active control study of the enzyme replacement therapy (ERT) drug PRX-102 (pegunigalsidase alfa) in Fabry disease patients with impaired renal function. Patients who had been treated for approximately 1 year with agalsidase beta and who had been on a stable dose of that product for at least 6 months were randomized in a 2:1 ratio to either switch to PRX-102 or to continue treatment with agalsidase beta. Both treatments were delivered by intravenous infusions every two weeks, at a dosage of 1 mg/kg.

NCT ID: NCT02793609 Completed - Prolonged Pregnancy Clinical Trials

Outpatient Versus Inpatient Balloon Catheter Induction of Labor

Start date: June 1, 2016
Phase: N/A
Study type: Interventional

Randomized trial comparing double balloon catheter for induction of labor between in- and outpatient groups.Investigators assess feasibility, clinical effectiveness and patient acceptability of outpatient versus inpatient catheter for induction of labor.

NCT ID: NCT02792660 Completed - Clinical trials for Pediatric Lumbar Puncture

Identification of Cerebrospinal Fluid With Injeq IQ-Needle During Paediatric Lumbar Puncture

Start date: July 2016
Phase: N/A
Study type: Interventional

This is clinical feasibility study on the device performance with paediatric patients. The main objective is to validate the performance of investigational device in distinguishing and identifying the cerebrospinal fluid (CSF) inside the subarachnoid space during a lumbar puncture on paediatric patients.

NCT ID: NCT02792231 Completed - Clinical trials for Relapsing Multiple Scelrosis

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

ASCLEPIOS II
Start date: August 26, 2016
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis

NCT ID: NCT02788513 Completed - Alzheimer Disease Clinical Trials

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Start date: August 11, 2016
Phase: Phase 2
Study type: Interventional

The study is designed to compare the effects of BI 425809 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease.

NCT ID: NCT02788474 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment

Start date: June 9, 2016
Phase: Phase 4
Study type: Interventional

Identifying biomarkers to predict the clinical course and benefits of therapy early in the course of the disease remains one of the most urgent and relevant challenges to improve overall patient management, to prevent treatment delay or overtreatment. This study is conducted to examine the effect of nintedanib treatment on change in biomarkers indicative of extracellular matrix turnover which have been shown recently to correlate with disease progression. This study further aims to confirm the association of biomarker course during the first three months of treatment and disease progression.